|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNIP1 |
Gene summary for TNIP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNIP1 | Gene ID | 10318 |
| Gene name | TNFAIP3 interacting protein 1 | |
| Gene Alias | ABIN-1 | |
| Cytomap | 5q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A0A0MRZ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10318 | TNIP1 | AEH-subject1 | Human | Endometrium | AEH | 2.79e-12 | 4.60e-01 | -0.3059 |
| 10318 | TNIP1 | AEH-subject2 | Human | Endometrium | AEH | 3.07e-02 | 1.88e-01 | -0.2525 |
| 10318 | TNIP1 | AEH-subject3 | Human | Endometrium | AEH | 1.77e-07 | 3.50e-01 | -0.2576 |
| 10318 | TNIP1 | AEH-subject4 | Human | Endometrium | AEH | 1.96e-03 | 3.08e-01 | -0.2657 |
| 10318 | TNIP1 | EEC-subject1 | Human | Endometrium | EEC | 2.04e-04 | 2.36e-01 | -0.2682 |
| 10318 | TNIP1 | EEC-subject2 | Human | Endometrium | EEC | 4.91e-05 | 2.86e-01 | -0.2607 |
| 10318 | TNIP1 | EEC-subject3 | Human | Endometrium | EEC | 9.34e-10 | 2.35e-01 | -0.2525 |
| 10318 | TNIP1 | EEC-subject4 | Human | Endometrium | EEC | 5.89e-05 | 1.88e-01 | -0.2571 |
| 10318 | TNIP1 | GSM5276934 | Human | Endometrium | EEC | 3.88e-17 | 5.25e-01 | -0.0913 |
| 10318 | TNIP1 | GSM5276937 | Human | Endometrium | EEC | 2.49e-10 | 4.23e-01 | -0.0897 |
| 10318 | TNIP1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.98e-08 | 8.45e-02 | -0.1869 |
| 10318 | TNIP1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.86e-06 | 7.24e-02 | -0.1875 |
| 10318 | TNIP1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.20e-09 | 1.41e-01 | -0.1883 |
| 10318 | TNIP1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.56e-12 | -4.24e-03 | -0.1934 |
| 10318 | TNIP1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.66e-14 | -3.95e-02 | -0.1917 |
| 10318 | TNIP1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.41e-10 | -1.04e-01 | -0.1916 |
| 10318 | TNIP1 | LZE4T | Human | Esophagus | ESCC | 1.92e-18 | 4.01e-01 | 0.0811 |
| 10318 | TNIP1 | LZE5T | Human | Esophagus | ESCC | 7.45e-09 | 3.11e-01 | 0.0514 |
| 10318 | TNIP1 | LZE7T | Human | Esophagus | ESCC | 1.37e-12 | 4.49e-01 | 0.0667 |
| 10318 | TNIP1 | LZE8T | Human | Esophagus | ESCC | 1.03e-12 | 4.73e-01 | 0.067 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
| GO:007121910 | Oral cavity | OSCC | cellular response to molecule of bacterial origin | 112/7305 | 221/18723 | 2.64e-04 | 1.69e-03 | 112 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00022243 | Oral cavity | OSCC | toll-like receptor signaling pathway | 63/7305 | 121/18723 | 2.36e-03 | 1.04e-02 | 63 |
| GO:00703735 | Oral cavity | OSCC | negative regulation of ERK1 and ERK2 cascade | 43/7305 | 78/18723 | 2.80e-03 | 1.22e-02 | 43 |
| GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
| GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
| GO:00440031 | Oral cavity | OSCC | modulation by symbiont of host process | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
| GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
| GO:00900858 | Oral cavity | OSCC | regulation of protein deubiquitination | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
| GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
| GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
| GO:190332026 | Oral cavity | EOLP | regulation of protein modification by small protein conjugation or removal | 73/2218 | 242/18723 | 1.41e-14 | 6.47e-12 | 73 |
| GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
| GO:004586226 | Oral cavity | EOLP | positive regulation of proteolysis | 91/2218 | 372/18723 | 7.08e-12 | 1.15e-09 | 91 |
| GO:001603226 | Oral cavity | EOLP | viral process | 94/2218 | 415/18723 | 2.93e-10 | 2.58e-08 | 94 |
| GO:000715917 | Oral cavity | EOLP | leukocyte cell-cell adhesion | 86/2218 | 371/18723 | 5.01e-10 | 4.11e-08 | 86 |
| GO:001905826 | Oral cavity | EOLP | viral life cycle | 72/2218 | 317/18723 | 3.11e-08 | 1.24e-06 | 72 |
| GO:001907925 | Oral cavity | EOLP | viral genome replication | 38/2218 | 131/18723 | 9.10e-08 | 3.15e-06 | 38 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa0513136 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa0513139 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131114 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0513122 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa0513132 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0513130 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa05131113 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa0513146 | Oral cavity | EOLP | Shigellosis | 61/1218 | 247/8465 | 9.48e-06 | 5.47e-05 | 3.23e-05 | 61 |
| hsa0513156 | Oral cavity | EOLP | Shigellosis | 61/1218 | 247/8465 | 9.48e-06 | 5.47e-05 | 3.23e-05 | 61 |
| hsa0513163 | Oral cavity | NEOLP | Shigellosis | 62/1112 | 247/8465 | 1.93e-07 | 2.79e-06 | 1.75e-06 | 62 |
| hsa0513173 | Oral cavity | NEOLP | Shigellosis | 62/1112 | 247/8465 | 1.93e-07 | 2.79e-06 | 1.75e-06 | 62 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNIP1 | SNV | Missense_Mutation | novel | c.1882N>G | p.Pro628Ala | p.P628A | Q15025 | protein_coding | tolerated_low_confidence(0.79) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| TNIP1 | SNV | Missense_Mutation | novel | c.139G>C | p.Glu47Gln | p.E47Q | Q15025 | protein_coding | deleterious(0.04) | probably_damaging(0.982) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| TNIP1 | SNV | Missense_Mutation | c.350N>A | p.Pro117Gln | p.P117Q | Q15025 | protein_coding | deleterious(0.03) | possibly_damaging(0.576) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TNIP1 | SNV | Missense_Mutation | rs750825606 | c.915N>A | p.Met305Ile | p.M305I | Q15025 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TNIP1 | SNV | Missense_Mutation | c.391N>A | p.Glu131Lys | p.E131K | Q15025 | protein_coding | deleterious(0) | benign(0.22) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TNIP1 | SNV | Missense_Mutation | rs751538216 | c.898N>A | p.Glu300Lys | p.E300K | Q15025 | protein_coding | deleterious(0.02) | possibly_damaging(0.662) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TNIP1 | insertion | Nonsense_Mutation | novel | c.137-1_137insCATGCCTTCAGTGTTGAGAGGCTCACCACTGCCTCA | p.Gly46delinsAlaCysLeuGlnCysTerGluAlaHisHisCysLeuArg | p.G46delinsACLQC*EAHHCLR | Q15025 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| TNIP1 | insertion | Frame_Shift_Ins | novel | c.140_141insAGCTGGGCTTGCCTGTT | p.Leu48AlafsTer25 | p.L48Afs*25 | Q15025 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| TNIP1 | insertion | In_Frame_Ins | novel | c.138_139insAAGCTGAGGCCCAGGGAA | p.Gly46_Glu47insLysLeuArgProArgGlu | p.G46_E47insKLRPRE | Q15025 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| TNIP1 | deletion | Frame_Shift_Del | novel | c.850delN | p.Ser284ValfsTer2 | p.S284Vfs*2 | Q15025 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |